Skip to Main content Skip to Navigation
Poster communications

Subcutaneous Tocilizumab in Monotherapy or in Combination with DMARD in Patients with Moderate to Severe Active Rheumatoid Arthritis: Observational Study to Describe Real-World Drug Retention Rate at 12 Months, Interim Analysis

Document type :
Poster communications
Complete list of metadatas

https://hal.univ-brest.fr/hal-01950797
Contributor : Geneviève Michel <>
Submitted on : Tuesday, December 11, 2018 - 9:26:15 AM
Last modification on : Wednesday, December 12, 2018 - 1:43:27 AM

Identifiers

  • HAL Id : hal-01950797, version 1

Collections

Citation

P. Hilliquin, T Barnetche, G Baudens, R. Niarra, I Idier, et al.. Subcutaneous Tocilizumab in Monotherapy or in Combination with DMARD in Patients with Moderate to Severe Active Rheumatoid Arthritis: Observational Study to Describe Real-World Drug Retention Rate at 12 Months, Interim Analysis. ACR/ARHP Annual Meeting, Oct 2018, Chicago, France. 70 (suppl 10) (Abstract 573), Arthritis Rheumatology. ⟨hal-01950797⟩

Share

Metrics

Record views

29